All four of the projects in this SPORE include clinical trials using cellular immunotherapy. These require a GMP manufacturing facility for the preparation of clinical grade vectors-and cellular therapy products. The GMP Facilities at the Center for Cell and Gene Therapy have been in operation for more than 13 years, recently relocating to one of the largest and most modern academic facilities of its type. The Cell Processing Facility (CPF) has considerable experience in the preparation of a wide variety of cellular products, including all that would be prepared for the SPORE projects. The CPF has been designated one of five National Somatic Cell Therapy Processing Facilities by the NHLBI under its Production Assistance for Cell Therapy Contract Program. The Vector Production Facility, which would also be a part of the Core, has produced more than 50 clinical grade adeno and retroviral vectors for local, national and international clinical studies and was a National Gene Vector Laboratory for adenoviral vectors. It also has considerable experience in manufacturing master and working cell banks. The final components of this Core are the Quality Control Laboratory, which performs in-house testing of cellular products and vectors, and is responsible for environmental monitoring of the GMP areas, and the Quality Assurance Group that ensures compliance with GMP and provides independent overview of all aspects of product manufacturing, testing, release and distribution. The GMP staff also have extensive regulatory experience that will facilitate the translation of laboratory studies into clinical trials.

Public Health Relevance

The Cell Processing and Vector Production Core manufactures cells and vectors that are given to patients on clinical trials in a safe manner with appropriate quality control. It is an essential component of the SPORE since it provides services that are vital to the implementation of the clinical studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Rouce, Rayne H; Heslop, Helen E (2016) Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov 6:579-80
Yang, Liubin; Rodriguez, Benjamin; Mayle, Allison et al. (2016) DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. Cancer Cell 29:922-34
Bollard, Catherine M; Heslop, Helen E (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127:3331-40
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2016) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol :
Ramos, Carlos A; Heslop, Helen E; Brenner, Malcolm K (2016) CAR-T Cell Therapy for Lymphoma. Annu Rev Med 67:165-83
Ramos, Carlos A; Savoldo, Barbara; Torrano, Vicky et al. (2016) Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 126:2588-96
Rau, Rachel E; Rodriguez, Benjamin A; Luo, Min et al. (2016) DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128:971-81
Zhou, Xiaoou; Naik, Swati; Dakhova, Olga et al. (2016) Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther 24:823-31
Eckstein, Olive S; Wang, Linghua; Punia, Jyotinder N et al. (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44:740-4
Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1

Showing the most recent 10 out of 218 publications